This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Peter H. Rheinstein, MD, JD, MS

JAMA. 1990;263(18):2491-2492.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Hendeles and colleagues¹ report on three patients, each of whom took the same defective pancreatic enzyme product and each of whom obtained an unsatisfactory result. The product consisted of capsules of pancrelipase, US Pharmacopeia (USP) formulated into enteric-coated spheres. The product was sold under various names, but all brands were manufactured by and were labeled as having been manufactured by Anabolic, Inc of Irvine, Calif.

Information regarding the defective product, including reports of testing conducted by the independent laboratory (Pharmichem Testing Services) and by a competitor, had been received at the Food and Drug Administration (FDA) by May 1989. The FDA's inspection of the firm revealed that there was no validation for the enteric coating process. Testing conducted by the firm confirmed that the enteric coating was ineffective. All lots were either subpotent or superpotent for one or more active ingredients.

On June 14,1989, the manufacturer voluntarily instituted a . . . [Full Text PDF of this Article]

Author Affiliations
From the Office of Drug Standards, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md.

Footnotes
Reprint requests to Office of Drug Standards (HFD-200), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Ln, Rockville, MD 20857 (Dr Rheinstein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?